12:00 AM
Feb 02, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Alagebrium: Phase II discontinued

Synvista plans to discontinue the Dutch Phase II BENEFICIAL trial to conserve resources. The trial was designed to evaluate 200 mg of oral...

Read the full 92 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >